EMA Application withdrawn: Heplisav — Dynavax International B.V.

View source ↗

Summary

The EMA withdrew the application for Heplisav by Dynavax International B.V. for hepatitis B indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• HEPLISAV (hepatitis B vaccine)

Snippet

Status: Application withdrawn. Therapeutic area: Hepatitis B. MAH: Dynavax International B.V.. Decision date: 21/02/2014